Less than $10/month! Screen on your Watchlists and Portfolios with Barchart Plus. FREE 30 Day Trial
or

Marvel Biosciences Corp (MRVL.VN)

Marvel Biosciences Corp (MRVL.VN)
0.135 unch (unch) 03/07/25 [TSX Venture]
0.135 x 5,000 0.140 x 15,000
Realtime by (Cboe BZX)
0.135 x 5,000 0.140 x 15,000
Realtime - - (-) -
Quote Overview for Fri, Mar 7th, 2025
Watch
    Add or delete the symbol from one or more Watchlists.
Day Low
0.135
Day High
0.140
Open 0.140
Previous Close 0.135 0.135
Volume 26,565 26,565
Avg Vol 43,158 43,158
Stochastic %K 34.52% 34.52%
Weighted Alpha +3.74 +3.74
5-Day Change -0.005 (-3.57%) -0.005 (-3.57%)
52-Week Range 0.060 - 0.185 0.060 - 0.185
  • 1D
  • 5D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
  • MAX
Full Chart
  • OHLC Bars
  • Colored OHLC Bars
  • HLC Bars
  • Candlestick Hollow
  • Candlestick Open-to-Close
  • Candlestick Close-to-Close
  • Heikin-Ashi
  • Line Chart
  • Area Chart
  • Renko
  • Column
  • Baseline
  • Line Break
  • Range
  • Kagi
  • Point And Figure

Fundamentals

See More
  • Market Capitalization, $K 6,049
  • Shares Outstanding, K 44,804
  • Annual Sales, $ 0 K
  • Annual Income, $ -1,650 K
  • EBIT $ N/A
  • EBITDA $ N/A
  • 60-Month Beta 0.28
  • Price/Sales N/A
  • Price/Cash Flow N/A
  • Price/Book N/A
  • Price/Earnings ttm N/A
  • Earnings Per Share ttm -0.04
  • Most Recent Earnings $-0.01 on 12/18/24
  • Next Earnings Date N/A
  • Annual Dividend & Yield N/A (N/A)
  • Most Recent Dividend N/A on N/A
  • Sector Medical
  • INDUSTRY GROUPING:

    TSX Biotechnology

Price Performance

See More
Period Period Low Period High Performance
1-Month
0.120 +12.50%
on 03/06/25
Period Open: 0.155
0.160 -15.62%
on 02/21/25
-0.020 (-12.90%)
since 02/07/25
3-Month
0.120 +12.50%
on 03/06/25
Period Open: 0.155
0.175 -22.86%
on 12/18/24
-0.020 (-12.90%)
since 12/06/24
52-Week
0.060 +125.00%
on 05/17/24
Period Open: 0.145
0.185 -27.03%
on 03/25/24
-0.010 (-6.90%)
since 03/07/24

Most Recent Stories

More News
Marvel Biosciences Announces Notice of Allowance of Composition of Matter Patent for Its Lead Molecule MB-204 in China

Calgary, Alberta--(Newsfile Corp. - January 16, 2025) - Marvel Biosciences Corp. (TSXV: MRVL) (OTCQB: MBCOF), and its wholly owned subsidiary, Marvel Biotechnology Inc. (collectively the "Company" or "Marvel"),...

MRVL.VN : 0.135 (unch)
MBCOF : 0.1020 (+23.79%)
Marvel Biosciences Announces Private Placement for up to $2.5 Million

Calgary, Alberta--(Newsfile Corp. - January 7, 2025) - Marvel Biosciences Corp. (TSXV: MRVL) (OTCQB: MBCOF) ("Marvel" or the "Company") is pleased to announce that it intends to complete a non-brokered...

MRVL.VN : 0.135 (unch)
Marvel Biosciences Announces Promising New Data from Rett Syndrome Study and Plans to Discuss Orphan and Rare Disease Status with the FDA

Calgary, Alberta--(Newsfile Corp. - November 26, 2024) - Marvel Biosciences Corp. (TSXV: MRVL) (OTCQB: MBCOF), and its wholly owned subsidiary, Marvel Biotechnology Inc. (collectively the "Company" or...

MRVL.VN : 0.135 (unch)
MBCOF : 0.1020 (+23.79%)
Marvel Biosciences Secures $300,000 Grant to Advance Groundbreaking Alzheimer's Research

Calgary, Alberta--(Newsfile Corp. - November 21, 2024) - Marvel Biosciences Corp. (TSXV: MRVL) (OTCQB: MBCOF), and its wholly owned subsidiary, Marvel Biotechnology Inc. (collectively the "Company" or...

MRVL.VN : 0.135 (unch)
MBCOF : 0.1020 (+23.79%)
Marvel Biosciences Announces MB204 Outperforms Approved Drug Trofinetide in a Preclinical Model of Rett Syndrome

Calgary, Alberta--(Newsfile Corp. - November 7, 2024) - Marvel Biosciences Corp. (TSXV: MRVL) (OTCQB: MBCOF), and its wholly owned subsidiary, Marvel Biotechnology Inc. (collectively the "Company" or "Marvel"),...

MRVL.VN : 0.135 (unch)
MBCOF : 0.1020 (+23.79%)
Marvel Biosciences Shares Positive Results of MB204 in the Oprm1 Model of Autism

Calgary, Alberta--(Newsfile Corp. - October 10, 2024) - Marvel Biosciences Corp. (TSXV: MRVL) (OTCQB: MBCOF), and its wholly owned subsidiary, Marvel Biotechnology Inc. (collectively the "Company" or "Marvel"),...

MRVL.VN : 0.135 (unch)
MBCOF : 0.1020 (+23.79%)
Marvel Announces Its Collaboration with FRAXA to Test MB204 In Pre-Clinical Models of Fragile X Syndrome

Calgary, Alberta--(Newsfile Corp. - August 13, 2024) - Marvel Biosciences Corp. (TSXV: MRVL) (OTCQB: MBCOF), and its wholly owned subsidiary, Marvel Biotechnology Inc. (collectively the "Company" or "Marvel"),...

MBCOF : 0.1020 (+23.79%)
MRVL.VN : 0.135 (unch)
Marvel Biosciences Announces Stock Option Grants

Calgary, Alberta--(Newsfile Corp. - July 25, 2024) - Marvel Biosciences Corp. (TSXV: MRVL) and its wholly owned subsidiary, Marvel Biotechnology Inc. (collectively the "Company" or "Marvel"), announce...

MBCOF : 0.1020 (+23.79%)
MRVL.VN : 0.135 (unch)
Marvel Announces an Extension to Its Collaboration with The iBraiN Institute to Test MB204 In a Pre-Clinical Model of Rett Syndrome

Calgary, Alberta--(Newsfile Corp. - July 24, 2024) - Marvel Biosciences Corp. (TSXV: MRVL) (OTCQB: MBCOF), and its wholly owned subsidiary, Marvel Biotechnology Inc. (collectively the "Company" or "Marvel"),...

MBCOF : 0.1020 (+23.79%)
MRVL.VN : 0.135 (unch)
Marvel Biosciences Closes Private Placement

Calgary, Alberta--(Newsfile Corp. - July 19, 2024) - Marvel Biosciences Corp. (TSXV: MRVL) and its wholly owned subsidiary, Marvel Biotechnology Inc. (collectively the "Company" or "Marvel"), is pleased...

MBCOF : 0.1020 (+23.79%)
MRVL.VN : 0.135 (unch)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 8% Sell with a Weakest short term outlook on maintaining the current direction.

See More Share

Business Summary

Marvel Biosciences Corp is a life sciences company focused on the discovery and development of a synthetic derivative compound of a known drug. It has developed several new chemical entities, using synthetic chemical derivatives of known, off-patent drugs, that inhibit the A2a adenosine receptor with...

See More

Key Turning Points

3rd Resistance Point 0.143
2nd Resistance Point 0.142
1st Resistance Point 0.138
Last Price 0.135
1st Support Level 0.133
2nd Support Level 0.132
3rd Support Level 0.128

See More

52-Week High 0.185
Fibonacci 61.8% 0.137
Last Price 0.135
Fibonacci 50% 0.123
Fibonacci 38.2% 0.108
52-Week Low 0.060

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.
Free Barchart Webinar
How to Trade Futures Spreads Like a Pro – Unlock Powerful Market Insights